{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:41:56Z","timestamp":1784346116709,"version":"3.55.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Concerns that take-home naloxone (THN) training may lead to riskier drug use (as a form of overdose risk compensation) remain a substantial barrier to training implementation. However, there was limited good-quality evidence in a systematic review of the association between THN access and subsequent risk compensation behaviors.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess whether THN training is associated with changes in overdose risk behaviors, indexed through injecting frequency, in a cohort of people who inject drugs.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used prospectively collected self-reported behavioral data before and after THN training of participants in The Melbourne Injecting Drug User Cohort Study (SuperMIX). Annual interviews were conducted in and around Melbourne, Victoria, Australia, from 2008 to 2021. SuperMIX participants were adults who regularly injected heroin or methamphetamine in the 6 months preceding their baseline interview. The current study included only people who inject drugs who reported THN training and had participated in at least 1 interview before THN training.<\/jats:p><\/jats:sec>Exposure<\/jats:title>In 2017, the SuperMIX baseline or follow-up survey began asking participants if and when they had received THN training. The first THN training date that was recorded was included as the exposure variable. Subsequent participant interviews were excluded from analysis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Injecting frequency was the primary outcome and was used as an indicator of overdose risk. Secondary outcomes were opioid injecting frequency, benzodiazepine use frequency, and the proportion of the time drugs were used alone. Fixed-effects generalized linear (Poisson) multilevel modeling was used to estimate the association between THN training and the primary and secondary outcomes. Time-varying covariates included housing status, income, time in study, recent opioid overdose, recent drug treatment, and needle and syringe coverage. Findings were expressed as incidence rate ratios (IRRs) with 95% CIs.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 1328 participants (mean [SD] age, 32.4 [9.0] years; 893 men [67.2%]) who completed a baseline interview in the SuperMIX cohort, and 965 participants completed either a baseline or follow-up interview in or after 2017. Of these 965 participants, 390 (40.4%) reported THN training. A total of 189 people who inject drugs had pretraining participant interviews with data on injecting frequency and were included in the final analysis (mean [SD] number of interviews over the study period, 6.2 [2.2]). In fixed-effects regression analyses adjusted for covariates, there was no change in the frequency of injecting (IRR, 0.91; 95% CI, 0.69-1.20; P<\/jats:italic>\u2009=\u2009.51), opioid injecting (IRR, 0.95; 95% CI, 0.74-1.23; P<\/jats:italic>\u2009=\u2009.71), benzodiazepine use (IRR, 0.96; 95% CI, 0.69-1.33; P<\/jats:italic>\u2009=\u2009.80), or the proportion of reported time of using drugs alone (IRR, 1.04; 95% CI, 0.86-1.26; P<\/jats:italic>\u2009=\u2009.67) before and after THN training.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study of people who inject drugs found no evidence of an increase in injecting frequency, along with other markers of overdose risk, after THN training and supply. The findings suggest that THN training should not be withheld because of concerns about risk compensation and that advocacy for availability and uptake of THN is required to address unprecedented opioid-associated mortality.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.27319","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T15:31:05Z","timestamp":1691163065000},"page":"e2327319","source":"Crossref","is-referenced-by-count":16,"title":["Injection Drug Use Frequency Before and After Take-Home Naloxone Training"],"prefix":"10.1001","volume":"6","author":[{"given":"Samantha","family":"Colledge-Frisby","sequence":"first","affiliation":[{"name":"National Drug Research Institute, Curtin University, Melbourne, Victoria, Australia"},{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"National Drug and Alcohol Research Centre, University of New South Wales (UNSW) Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasun","family":"Rathnayake","sequence":"additional","affiliation":[{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash Addiction Research Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stoove","sequence":"additional","affiliation":[{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Agius","sequence":"additional","affiliation":[{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Faculty of Health, Deakin University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Higgs","sequence":"additional","affiliation":[{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Department of Public Health, La Trobe University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[{"name":"National Drug Research Institute, Curtin University, Melbourne, Victoria, Australia"},{"name":"Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"7044","key":"zoi230789r1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1136\/bmj.312.7044.1435","article-title":"Heroin overdose: the case for take-home naloxone.","volume":"312","author":"Strang","year":"1996","journal-title":"BMJ"},{"issue":"4","key":"zoi230789r2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/dar.2018.37.issue-4","article-title":"Take-home naloxone in Australia and beyond.","volume":"37","author":"Olsen","year":"2018","journal-title":"Drug Alcohol Rev"},{"key":"zoi230789r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.038","article-title":"Impact of a community-based naloxone distribution program on opioid overdose death rates.","volume":"204","author":"Naumann","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi230789r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103513","article-title":"Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a \u2018moral hazard\u2019 associated with naloxone supply.","volume":"100","author":"Tse","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi230789r5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/08897077.2017.1303424","article-title":"Medical providers\u2019 knowledge and concerns about opioid overdose education and take-home naloxone rescue kits within Veterans Affairs health care medical treatment settings.","volume":"38","author":"Winograd","year":"2017","journal-title":"Subst Abus"},{"issue":"2","key":"zoi230789r6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/08897077.2019.1616348","article-title":"Concerns that an opioid antidote could \u201cmake things worse\u201d: profiles of risk compensation beliefs using the Naloxone-Related Risk Compensation Beliefs (NaRRC-B) scale.","volume":"41","author":"Winograd","year":"2020","journal-title":"Subst Abus"},{"issue":"7","key":"zoi230789r7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3109\/10826084.2013.787099","article-title":"Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders.","volume":"48","author":"Green","year":"2013","journal-title":"Subst Use Misuse"},{"issue":"1","key":"zoi230789r8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11524-006-9120-z","article-title":"Physicians\u2019 knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities.","volume":"84","author":"Beletsky","year":"2007","journal-title":"J Urban Health"},{"key":"zoi230789r9","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia.","volume":"57","author":"Thornton","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"zoi230789r10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1186\/s12889-022-13298-3","article-title":"Beliefs and misperceptions about naloxone and overdose among U.S. laypersons: a cross-sectional study.","volume":"22","author":"Agley","year":"2022","journal-title":"BMC Public Health"},{"issue":"13","key":"zoi230789r11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1080\/10826084.2016.1197267","article-title":"Public perspectives on expanding naloxone access to reverse opioid overdoses.","volume":"51","author":"Rudski","year":"2016","journal-title":"Subst Use Misuse"},{"issue":"3","key":"zoi230789r12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/safety2030016","article-title":"Risk compensation: revisited and rebutted.","volume":"2","author":"Pless","year":"2016","journal-title":"Safety (Basel)"},{"issue":"2","key":"zoi230789r13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/ip.6.2.82","article-title":"Risky business: safety regulations, risks compensation, and individual behavior.","volume":"6","author":"Hedlund","year":"2000","journal-title":"Inj Prev"},{"issue":"12","key":"zoi230789r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081997","article-title":"No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.","volume":"8","author":"Marcus","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"zoi230789r15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/virtualmentor.2014.16.11.stas1-1411","article-title":"Will risk compensation accompany pre-exposure prophylaxis for HIV?","volume":"16","author":"Blumenthal","year":"2014","journal-title":"Virtual Mentor"},{"issue":"6","key":"zoi230789r16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMp1810743","article-title":"Risk compensation and clinical decision making\u2014the case of HIV preexposure prophylaxis.","volume":"380","author":"Marcus","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi230789r17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.drugpo.2012.03.006","article-title":"Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research.","volume":"23","author":"Hyshka","year":"2012","journal-title":"Int J Drug Policy"},{"key":"zoi230789r18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1186\/s12889-015-2604-6","article-title":"Non-fatal overdoses and related risk factors among people who inject drugs in St. Petersburg, Russia and Kohtla-J\u00e4rve, Estonia.","volume":"15","author":"Uusk\u00fcla","year":"2015","journal-title":"BMC Public Health"},{"issue":"1","key":"zoi230789r19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12954-018-0240-z","article-title":"Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD.","volume":"15","author":"Park","year":"2018","journal-title":"Harm Reduct J"},{"issue":"8","key":"zoi230789r20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1046\/j.1360-0443.2001.96811135.x","article-title":"Heroin overdose: causes and consequences.","volume":"96","author":"Warner-Smith","year":"2001","journal-title":"Addiction"},{"issue":"5","key":"zoi230789r21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/add.2005.100.issue-5","article-title":"Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose.","volume":"100","author":"Dietze","year":"2005","journal-title":"Addiction"},{"issue":"3","key":"zoi230789r22","doi-asserted-by":"publisher","DOI":"10.1177\/1557988319859113","article-title":"The opioid overdose epidemic and the urgent need for effective public health interventions that address men who use drugs alone.","volume":"13","author":"Bardwell","year":"2019","journal-title":"Am J Mens Health"},{"issue":"2","key":"zoi230789r23","first-page":"4","article-title":"Community-based naloxone: a Canadian pilot program.","volume":"3","author":"Dong","year":"2012","journal-title":"Can J Addict"},{"issue":"3","key":"zoi230789r24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drugpo.2009.01.003","article-title":"Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA.","volume":"21","author":"Wagner","year":"2010","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi230789r25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/dar.v39.1","article-title":"Designing, implementing and evaluating the overdose response with take-home naloxone model of care: an evaluation of client outcomes and perspectives.","volume":"39","author":"Lintzeris","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"zoi230789r26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jurban\/jti053","article-title":"Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study.","volume":"82","author":"Seal","year":"2005","journal-title":"J Urban Health"},{"key":"zoi230789r27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addbeh.2017.03.008","article-title":"No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.","volume":"71","author":"Jones","year":"2017","journal-title":"Addict Behav"},{"issue":"2","key":"zoi230789r28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/09595239800187001","article-title":"Route of drug use and its implications for drug effect, risk of dependence and health consequences.","volume":"17","author":"Strang","year":"1998","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"zoi230789r29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.addbeh.2012.01.019","article-title":"Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users.","volume":"37","author":"Kinner","year":"2012","journal-title":"Addict Behav"},{"issue":"1","key":"zoi230789r30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/10826080701205109","article-title":"A cross-sectional study on prevalence of non-fatal drug overdose and associated risk characteristics among out-of-treatment injecting drug users in North Vietnam.","volume":"43","author":"Bergenstrom","year":"2008","journal-title":"Subst Use Misuse"},{"key":"zoi230789r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102619","article-title":"Frequency of injecting among people who inject drugs: a systematic review and meta-analysis.","volume":"76","author":"Colledge","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi230789r32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11524-010-9525-6","article-title":"Risk factors for nonfatal overdose at Seattle-area syringe exchanges.","volume":"88","author":"Jenkins","year":"2011","journal-title":"J Urban Health"},{"issue":"3","key":"zoi230789r33","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1093\/ije\/dyab231","article-title":"Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX).","volume":"51","author":"Van Den Boom","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"1","key":"zoi230789r34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12913-016-1668-z","article-title":"Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis.","volume":"16","author":"O\u2019Keefe","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"zoi230789r35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/dar.2018.37.issue-4","article-title":"An overview of take-home naloxone programs in Australia.","volume":"37","author":"Dwyer","year":"2018","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"zoi230789r38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drugalcdep.2006.02.005","article-title":"When is a little knowledge dangerous? circumstances of recent heroin overdose and links to knowledge of overdose risk factors.","volume":"84","author":"Dietze","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"zoi230789r39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2019.07.030","article-title":"The prevalence of non-fatal overdose among people who inject drugs: a multi-stage systematic review and meta-analysis.","volume":"73","author":"Colledge","year":"2019","journal-title":"Int J Drug Policy"},{"key":"zoi230789r40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugpo.2018.03.026","article-title":"Safe and unsafe spaces: non-fatal overdose, arrest, and receptive syringe sharing among people who inject drugs in public and semi-public spaces in Baltimore City.","volume":"57","author":"Hunter","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"4355","key":"zoi230789r41","doi-asserted-by":"publisher","first-page":"j4355","DOI":"10.1136\/bmj.j4355","article-title":"Epidemic of deaths from fentanyl overdose.","volume":"358","author":"Soc\u00edas","year":"2017","journal-title":"BMJ"},{"key":"zoi230789r42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugpo.2017.09.015","article-title":"\u2018I have it just in case\u2019 - naloxone access and changes in opioid use behaviours.","volume":"51","author":"Heavey","year":"2018","journal-title":"Int J Drug Policy"},{"key":"zoi230789r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103061","article-title":"Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.","volume":"90","author":"Nielsen","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"10","key":"zoi230789r44","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/add.v110.10","article-title":"Naloxone\u2013does over-antagonism matter? evidence of iatrogenic harm after emergency treatment of heroin\/opioid overdose.","volume":"110","author":"Neale","year":"2015","journal-title":"Addiction"},{"key":"zoi230789r36","unstructured":"Victoria State Parliament. Saving lives: preventing and treating overdose. Accessed December 29, 2022. https:\/\/www.premier.vic.gov.au\/saving-lives-preventing-and-treating-overdose\/"},{"key":"zoi230789r37","unstructured":"Stata 16. Version 16. StataCorp LLC; 2019. Accessed December 29, 2022. https:\/\/www.stata.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808081\/colledgefrisby_2023_oi_230789_1690559489.09759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T15:31:11Z","timestamp":1691163071000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27319","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]}}}